Disease Areas
1ST Biotherapeutics is clinical-stage biotech dedicated to developing breakthrough therapies with an eventual goal of bringing forward novel medicines to patients. With a core R&D team passionate about problem-solving through rigorous research and scientific discipline, we are relentlessly advancing innovative therapeutic candidates with a high likelihood of clinical success.
1ST Biotherapeutics is clinical-stage biotech dedicated to developing breakthrough therapies with an eventual goal of bringing forward novel medicines to patients. With a core R&D team passionate about problem-solving through rigorous research and scientific discipline, we are relentlessly advancing innovative therapeutic candidates with a high likelihood of clinical success.
Neurodegenerative Diseases
FB-101 targets c-Abl, which has been shown to play a critical role in driving alpha-synuclein pathogenesis in Parkinson’s disease. Our current candidate has optimal properties as a CNS drug with potent neuroprotection activities and desirable safety profiles.
FB418 and 1ST-103 block a critical pathway in vicious inflammatory response followed by neurotoxicity, which leads to disease-modifying potential and broad-spectrum therapeutic options for Parkinson’s, Alzheimer’s and ALS.
Immuno-Oncology
1ST-201 targets a crucial pathway in immuno-oncology and aims to reverse the active immune suppression and stimulate functionality of effector immune cells and dendritic cells in tumor microenvironment.
We envision that 1ST-201 will provide novel therapeutic options as well as be a beneficial part of combination in immunotherapy with the objective of modulating multiple therapeutic opportunities for maximum benefits to cancer patients.
Rare Diseases
We recognize how the lack of effective therapies for rare diseases impacts patients and their families. With a novel therapeutic approach, we believe 1ST-301 and our rare disease program can provide solutions to a broad range of genetic diseases.